Pipeline
Will “Robust Pipeline” Yield More New Drugs?
A new PhRMA report documents more than 5,000 new medicines in the pipeline globally, many for untreated diseases and life-threatening conditions. But the data also reveals that most of these therapies are in early stages of development: less than 1000 of the 5400 products in clinical development have reached stage III, and only 82 are headed for market following approval by FDA ...Read more
Pricing
Reimbursing Specialty Drugs
To maximize return on investment, pharma must think strategically about reimbursement channels and how new specialty products will perform in one versus another, writes Ben Comer ...Read More
Marketing
Pharma’s Promotional Spend: What’s the Right Target?
A new survey on how and where Big Pharma puts its promotional dollar reveals that spending in emerging markets significantly increased last year, while Europe and US declined slightly. Beyond the numbers, the survey offers new insights on how budgets are being allocated among various channels ...Read more
Marketing
Why Don’t Those Damn Marketers ‘Do’ Digital
After years of thanklessly trying to preach and teach the virtues of digital channels, Sven Awege realizes that he might not have been looking at the problem through the right prism ...Read more
Special Feature
Can Regulatory Professionals Make Business Leaders?
Attracting skilled regulatory staff is crucial for your company. But do such individuals have a head for business and, if not, can you teach them?
...Read more
Global
Read the New Pharm Exec Global Digest
In the January 2013 issue: What Now for Greece? — Brazil’s War on AIDS — The African Markets Pharma Can’t Ignore — and Global Safety and Harmonization Efforts 2013 ...Read more
|
